on TuHURA Biosciences, Inc.
TuHURA Biosciences Set to Present at Virtual Investor Event
TuHURA Biosciences, Inc. (NASDAQ:HURA), a company at the forefront of immune-oncology, announced its participation in the Virtual Investor "New to the Street" Event on October 30, 2024. The event will feature Dr. Jim Bianco, the firm's President and CEO, who will provide an overview of TuHURA's corporate strategies and future business direction.
The company specializes in developing innovative technologies aimed at overcoming resistance to cancer immunotherapies. Its lead candidate, IFx-2.0, is undergoing Phase 3 trials as an adjunct therapy for Merkel Cell Carcinoma. Additionally, TuHURA is advancing its Delta receptor technology, targeting immune suppression in tumor environments.
The webcast will be accessible via the company’s website and a replay will be available for 90 days post-event, allowing broader access for interested parties.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all TuHURA Biosciences, Inc. news